FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Therapeutic effect and mechanism of sivelestat sodium on acute lung injury: A randomized controlled trial. PMID 41029079 · Medicine (Baltimore) · 2025-Sep-26 The study is a randomized controlled trial of a drug (sivelestat sodium) for acute lung injury, not a human malignant neoplasm. It lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as required for the cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hypothermic oxygenated perfusion (HOPE) against cancer recurrence after liver transplantation for hepatocellular carcinoma-study protocol for an international multicenter randomized controlled trial (HOPE4Cancer). PMID 41013675 · Trials · 2025-Sep-26 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Re-emergence of circulating non-malignant B cells as a prognostic biomarker in chronic lymphocytic leukaemia. PMID 41006384 · Sci Rep · 2025-Sep-26 The record is a secondary biomarker analysis from a phase III trial. It is not the original formal report of the randomized trial's primary or key secondary efficacy results. Therefore, it does not meet the inclusion criteria for an original result report of a Phase III randomized trial with a primary/key secondary time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Racial Differences in Symptom Burden and Endocrine Therapy Adherence in Breast Cancer: A Post Hoc Analysis of a Randomized Trial. PMID 41005350 · J Natl Compr Canc Netw · 2025-Sep-26 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Phase II randomised controlled basket feasibility trial of a personalised, remotely delivered exercise programme on disease-free survival among early-stage, high-risk cancers: CANFit study protocol. PMID 40998437 · BMJ Open · 2025-Sep-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Prognostic immune nutritional index-based nutritional stratification enhances recovery and survival in gastric cancer: A randomized controlled trial. PMID 41024831 · World J Clin Oncol · 2025-Sep-24 The record describes a randomized controlled trial in gastric cancer evaluating PINI-based nutritional support. However, it does not meet key eligibility criteria: the phase is not specified as Phase III/IIIb or Phase II/III, the intervention is non-drug nutritional support, and the primary endpoint is not a time-to-event efficacy endpoint with Kaplan-Meier or HR analysis. Therefore, it is excluded. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The IC3 trial: protocol for a multicentre individually randomised controlled trial to compare a cirrhosis detection and hepatocellular carcinoma surveillance pathway vs usual care in Australian general practice for 45-75 years old with risk factors for chronic liver disease. PMID 40993832 · Trials · 2025-Sep-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Curcumin Attenuates Liver Steatosis via Antioxidant and Anti-Inflammatory Pathways in Obese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. PMID 41096556 · Int J Mol Sci · 2025-Sep-23 The record is not an oncology study; it is a randomized controlled trial of curcumin for liver steatosis in Type 2 Diabetes. It lacks a drug-containing intervention per the criteria, does not have a primary time-to-event efficacy endpoint, and the phase is not established as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia. PMID 40505060 · Blood Adv · 2025-Sep-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Current Clinical Trial Landscape of Gastroenteropancreatic Neuroendocrine Tumors: A New Era of Landmark Trials. PMID 41010726 · J Clin Med · 2025-Sep-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Tumour-Infiltrating Lymphocytes, Tumour Cell Density, and Response to Neoadjuvant Short-Course Radiotherapy in Rectal Cancer: A Translational Sub-Study from the MRC CR07 Clinical Trial. PMID 41008883 · Cancers (Basel) · 2025-Sep-17 The study is a translational sub-study of the MRC CR07 trial, analyzing biomarkers (TCD and TIL) in a randomized trial of radiotherapy versus surgery. The intervention does not contain a drug, and the report focuses on biomarker prognostic/predictive value, not the primary efficacy analysis of a drug-containing Phase III/IIIb or Phase II/III randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial. PMID 40056158 · Neuro Oncol · 2025-Sep-17 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Clinical pharmacology and therapeutic applications of talazoparib: a comprehensive review. PMID 40956449 · Cancer Chemother Pharmacol · 2025-Sep-16 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial. PMID 40795846 · Cell Rep Med · 2025-Sep-16 The study is an oncology randomized trial with a drug intervention (berberine) and reports original results on adenoma recurrence. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III; it is an extended follow-up of a previous trial, but the original trial's phase is not specified in the record. The primary endpoint is adenoma recurrence (a categorical outcome), not a time-to-event endpoint (OS, PFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it fails the 'phase3_or_definitive' and 'time_to_event' criteria. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial. PMID 40036375 · Clin Infect Dis · 2025-Sep-16 The record is excluded because it lacks an explicit time-to-event primary/key secondary efficacy endpoint. The primary endpoint is histological resolution (binary), and while recurrence is analyzed with a log-rank test, the abstract does not provide KM estimates, medians, or HRs, so a time-to-event signal cannot be reliably established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Synergistic Effects of Psychological Resilience Training and Nutritional Support on Postoperative Recovery, Nutritional Reconstitution, Sleep Quality, and Long-Term Survival in Gastric Cancer: A Randomized Controlled Trial. PMID 40954394 · Ann Surg Oncol · 2025-Sep-15 The study is a randomized, oncology, human trial with primary time-to-event endpoints (DFS, OS) and original results. However, it does not meet the core eligibility requirement of a drug-containing intervention, as the intervention is psychological and nutritional support, not a pharmacological agent. The trial phase is also not explicitly stated as Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Two-Week Course versus Conventionally Fractionated Preoperative Chemoradiotherapy Followed by Total Mesorectal Excision in Locally Advanced Rectal Cancer (Twoarc Trial): A Phase III Randomized Clinical Trial. PMID 40939157 · Ann Surg · 2025-Sep-15 The study is a Phase III randomized trial with drug intervention, but its primary endpoint is pathologic response (downstaging rate), not a time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or an analysis using Kaplan-Meier or HR. Therefore, it does not meet the inclusion criterion for a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Durvalumab versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial. PMID 40705396 · Clin Cancer Res · 2025-Sep-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer. PMID 40673886 · Clin Cancer Res · 2025-Sep-15 Eligible: Phase III/definitive randomized controlled trial with drug intervention and primary time-to-event endpoint (rPFS) reported in an FDA approval summary. |
B
|
影子组漏检补回 | eligiblemodel_adjudicated_eligible | confirmed 1 Figure · 1 Panel · risk visible |
| Trajectories of Recovery after Intravenous propofol versus inhaled VolatilE anaesthesia (THRIVE) randomised controlled trial in the USA: A protocol. PMID 40953862 · BMJ Open · 2025-Sep-14 The record is a protocol for a randomised trial comparing anaesthetic techniques (propofol vs. volatile anaesthesia) in patients undergoing non-cardiac surgery. It is not an oncology trial, the primary endpoint is a patient-reported recovery score (QOR-15), and it reports no results. Therefore, it fails the core eligibility criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival on Extent of Lymphadenectomy for Right-Sided Colon Cancer: Five-Year Follow-up Results of a Randomized Controlled Trial (RELARC Trial). PMID 40938728 · Ann Surg · 2025-Sep-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial. PMID 40015729 · J Neurol Neurosurg Psychiatry · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Endovascular management of intracranial carotid blowout syndrome in patients with head and neck cancer. PMID 39237154 · J Neurointerv Surg · 2025-Sep-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial. PMID 40935571 · BMJ · 2025-Sep-11 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer. PMID 40763319 · J Clin Oncol · 2025-Sep-10 The report meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original result. However, the phase of the trial (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata, making eligibility indeterminate. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). PMID 40930564 · BMJ Open · 2025-Sep-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Using American Sign Language-Fluent Community Health Navigators to Advance Cancer Screening Adherence through Videoconferencing With Deaf, Deafblind, and Hard of Hearing Adults: Protocol for a Randomized Controlled Trial. PMID 40925603 · JMIR Res Protoc · 2025-Sep-09 The record is a protocol for a randomized controlled trial testing a non-drug intervention (ASL-fluent community health navigator) for cancer screening adherence, with primary/secondary outcomes being screening completion, communication, and knowledge. It does not present results from a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, and no time-to-event efficacy endpoint is specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial. PMID 40924208 · J Cancer Res Clin Oncol · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-related prognostic factors in older adults with head and neck cancer: The EGeSOR clinical trial. PMID 40684734 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. PMID 40921630 · J Immunother Cancer · 2025-Sep-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Impact of Intraoperative Lidocaine During Oncologic Lung Resection on Long-Term Outcomes in Primary Lung Cancer: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 40941021 · Cancers (Basel) · 2025-Sep-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effective nutritional intervention improves the health-related quality of life (HRQL) of undernourished children with cancer: results of a randomized, controlled phase 3 trial. PMID 40913629 · Support Care Cancer · 2025-Sep-06 The study is an oncology Phase III randomized controlled trial in humans with a primary result report, but it is excluded because the intervention is non-drug (nutritional) and the endpoint is not time-to-event efficacy. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial. PMID 41020329 · Br J Surg · 2025-Sep-02 The record is an original result report from a randomized Phase III trial (RAPIDO) in oncology with a drug intervention and a primary time-to-event endpoint (locoregional recurrence). Although the abstract focuses on subgroup analysis (sphincter-preserving vs. abdominoperineal resection), it reports results from the overall trial population and is not exclusively a post-hoc, biomarker, QoL, safety, or economic analysis. The abstract confirms the randomized, Phase III nature of the trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC). PMID 40898159 · BMC Cancer · 2025-Sep-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| CARBOMETASPINE: protocol for a multicenter, prospective, randomized controlled trial of carbonfiber spinal fixation in metastatic disease. PMID 40898139 · BMC Cancer · 2025-Sep-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Physical activity and mobility disability in older adult cancer survivors. PMID 40930715 · JNCI Cancer Spectr · 2025-Sep-01 The trial is a randomized clinical trial in older adults, but the intervention is a physical activity program, not a drug. While it includes cancer survivors as a subgroup, it is not a trial of a cancer treatment. Therefore, it does not meet the oncology drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. PMID 40890873 · Cardiooncology · 2025-Sep-01 The record describes the rationale and design of a randomized clinical trial but explicitly states it is ongoing with no results. It is a protocol report. Furthermore, the primary endpoint is cardiotoxicity incidence, which is not a time-to-event oncology efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. PMID 40890782 · Trials · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of a self-made dietary therapy formula on the improvement of enteral feeding intolerance in patients with laryngeal cancer after surgery: A randomized controlled trial. PMID 40888947 · Support Care Cancer · 2025-Sep-01 The study is an oncology RCT with original results, but it is excluded because: (1) it does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.)—the primary outcomes are complications and nutritional parameters; (2) the intervention is a non-drug dietary formula, not a drug; (3) the trial phase is not specified, and there is no signal for Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer. PMID 40888443 · Endocr Relat Cancer · 2025-Sep-01 Study is an eligible Phase III randomized drug trial in oncology, but its primary endpoints are pathological response scores (PEPI, EPclin), not a pre-specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Managing, not lessening, uncertainty: a novel mind-body intervention for fear of cancer recurrence. PMID 40887510 · J Cancer Surviv · 2025-Sep-01 Excluded: Not a Phase III/IIIb or Phase II/III randomized trial; no drug intervention; primary/key endpoint is not time-to-event; intervention is non-drug psycho-oncology; report is secondary analysis of pilot study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Physical fitness and clinically assessed disease burden in long-term childhood cancer survivors-The SURfit study. PMID 40831029 · Cancer · 2025-Sep-01 The study is a randomized trial in human cancer survivors, but it is not a Phase III trial with a drug intervention. The primary endpoint is disease burden (adverse health outcomes) and its association with physical fitness, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The intervention is physical activity/exercise, not a drug. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. PMID 40742738 · JAMA Oncol · 2025-Sep-01 The study is an oncology RCT with a drug intervention and original results, but it does not meet all required criteria: it is not a definitive Phase III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS) but a continuous measure of agitation severity. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. PMID 40638104 · JAMA Oncol · 2025-Sep-01 The record meets most eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result). However, it fails the explicit requirement for a Phase III/IIIb or Phase II/III trial, as the phase is not clearly stated in the provided metadata. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of tourniquet application on postoperative delirium in elderly patients undergoing total knee arthroplasty: a randomized clinical trial. PMID 40540295 · Int J Surg · 2025-Sep-01 This is a randomized clinical trial in humans, but it is not an oncology study (tourniquet use in total knee arthroplasty), lacks a time-to-event efficacy endpoint (primary outcome is incidence of delirium, not OS/PFS/etc.), and has no drug intervention (surgical/anesthesia-related). It does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. PMID 40515653 · J Natl Cancer Inst · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Carcinogen reduction in a randomized controlled study comparing e-cigarette provision to assessment only among people with serious mental illness who smoke. PMID 40505215 · Drug Alcohol Depend · 2025-Sep-01 The study is a randomized trial in humans with original results, but it is not an oncology trial (focus is harm reduction via e-cigarette provision to reduce carcinogen exposure, not treatment of a human malignant neoplasm). It does not involve a drug-containing intervention (e-cigarette provision is a device, not a drug). It does not report a time-to-event efficacy endpoint (primary outcome is biomarker change in NNAL, not OS, PFS, DFS, etc.). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| NOVEMBER, A Phase 2 Trial of a 9-Day Course of Whole Breast Radiation Therapy With a Simultaneous Lumpectomy Boost for Early-Stage Breast Cancer. PMID 40314623 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated Versus Single-Session Radiosurgery to Preserve Hearing in Patients Affected by Sporadic Vestibular Schwannoma: The ACOUNEU Randomized Clinical Trial. PMID 40222395 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The study is a randomized clinical trial in oncology with a time-to-event primary endpoint (hearing preservation hazard ratio) and reports primary results. However, it is not eligible because the intervention is not drug-containing (it compares two radiotherapy fractionation schedules, not a drug). Additionally, the trial phase is not explicitly confirmed as Phase III or a definitive trial in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A Randomized Comparison of High-Dose-Rate and Low-Dose-Rate Prostate Brachytherapy Combined With External Beam Radiation Therapy for Unfavorable Prostate Cancer: Efficacy Results After Median Follow-up of 74 Months. PMID 40187573 · Int J Radiat Oncol Biol Phys · 2025-Sep-01 The trial is randomized, human, oncologic, and reports time-to-event efficacy endpoints. However, it is ineligible because the intervention is not a drug-containing one; it compares two radiation therapy modalities (HDR vs. LDR brachytherapy). Additionally, the phase of the trial is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |